ANTX EBITDA | AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. (ANTX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$8.90M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$10.55M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$10.04M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$7.22M; Depreciation and amortization (m).

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$8.90M	(m)	(m)	(m)	(m)	-$7.00M*	(m)	$6.02M	(m)	(m)
2026-03-31	Reported	(m)	-$10.55M	(m)	(m)	(m)	(m)	-$12.07M	(m)	$6.74M	(m)	(m)
2025-09-30	Reported	(m)	-$10.04M	(m)	(m)	(m)	(m)	-$6.38M*	(m)	$7.00M	(m)	(m)
2025-06-30	Reported	(m)	-$7.22M	(m)	(m)	(m)	(m)	-$7.60M*	(m)	$3.20M	(m)	(m)
2025-03-31	Reported	(m)	-$11.54M	(m)	(m)	(m)	(m)	-$10.62M	(m)	$7.69M	(m)	(m)
2024-09-30	Reported	(m)	-$14.01M	(m)	(m)	(m)	(m)	-$12.01M*	(m)	$8.29M	(m)	(m)
2024-06-30	Reported	(m)	-$15.88M	(m)	(m)	(m)	(m)	-$14.38M*	(m)	$12.15M	(m)	(m)
2024-03-31	Reported	(m)	-$18.30M	(m)	(m)	(m)	(m)	-$17.59M	(m)	$14.65M	(m)	(m)
2023-09-30	Reported	(m)	-$18.18M	(m)	(m)	(m)	(m)	-$11.80M*	(m)	$14.43M	(m)	(m)
2023-06-30	Reported	(m)	-$16.60M	(m)	(m)	(m)	(m)	-$12.82M*	(m)	$13.54M	(m)	(m)
2023-03-31	Reported	(m)	-$16.04M	(m)	(m)	(m)	(m)	-$11.60M	(m)	$11.98M	(m)	(m)
2022-09-30	Reported	(m)	-$11.77M	(m)	(m)	(m)	(m)	-$9.49M*	(m)	$7.43M	(m)	(m)
2022-06-30	Reported	(m)	-$10.33M	(m)	(m)	(m)	(m)	-$9.60M*	(m)	$6.70M	(m)	(m)
2022-03-31	Reported	(m)	-$7.68M	(m)	(m)	(m)	(m)	-$6.74M	(m)	$5.63M	(m)	(m)
2021-09-30	Reported	(m)	-$6.93M	(m)	(m)	(m)	(m)	-$4.69M*	(m)	$5.34M	(m)	(m)
2021-06-30	Reported	(m)	-$5.00M	(m)	(m)	(m)	(m)	-$5.26M*	(m)	$3.85M	(m)	(m)
2021-03-31	Reported	(m)	-$2.05M	(m)	(m)	(m)	(m)	-$1.54M	(m)	$1.65M	(m)	(m)

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$38.11M	(m)	(m)	(m)	(m)	-$29.83M	(m)	$24.77M	(m)	$0.00
2024-12-31	Reported	(m)	-$56.79M	(m)	(m)	(m)	(m)	-$49.26M	(m)	$40.49M	(m)	$0.00
2023-12-31	Reported	(m)	-$69.64M	(m)	(m)	(m)	(m)	-$53.29M	(m)	$54.87M	(m)	$0.00
2022-12-31	Reported	(m)	-$42.26M	(m)	(m)	(m)	(m)	-$33.46M	(m)	$28.51M	(m)	$0.00
2021-12-31	Reported	(m)	-$21.57M	(m)	(m)	(m)	(m)	-$20.48M	(m)	$16.16M	(m)	$0.00

Stock Name	Country	Market Cap	PE Ratio
PepGen Inc. (PEPG)	United States	$0.186B	-1.73
ALX ONCOLOGY HOLDINGS INC (ALXO)	United States	$0.187B	-3.52
Organogenesis Holdings Inc. (ORGO)	United States	$0.182B	-3.70
Fortress Biotech, Inc. (FBIO)	United States	$0.188B	0.91
Zentalis Pharmaceuticals, Inc. (ZNTL)	United States	$0.196B	-2.48
ORAMED PHARMACEUTICALS INC. (ORMP)		$0.199B	1.13
Tonix Pharmaceuticals Holding Corp. (TNXP)	United States	$0.166B	-1.34
Minerva Neurosciences, Inc. (NERV)	United States	$0.165B	-0.66
Nkarta, Inc. (NKTX)	United States	$0.205B	-1.73
ADC Therapeutics SA (ADCT)		$0.163B	-1.39